Akkuzu Mustafa Zanyar, Ebik Berat
Department of Gastroenterology, Diyarbakır Gazi Yasargil Education and Research Hospital, University of Health Sciences, Diyarbakır 21070, Turkey.
Diagnostics (Basel). 2025 Aug 27;15(17):2173. doi: 10.3390/diagnostics15172173.
: This study aimed to determine the in-hospital mortality rate after upper gastrointestinal (GI) bleeding in geriatric patients with comorbidities. Additionally, it sought to identify effective cut-off values for predicting high-risk patients using AIMS65 and Rockall scores and to assess the impact of oral anticoagulant and NSAID use on mortality. : A retrospective cohort study was conducted on 64 patients aged 60 and above with at least one comorbidity who were admitted for upper GI bleeding between January 2023 and June 2024. AIMS65 and Rockall scores were calculated for each patient. The relationship between these scores, medication use, and mortality was analyzed using statistical methods, including ROC analysis and Kaplan-Meier survival curves. : The mean age was 77.6 years, and all patients had at least one chronic disease; 57.8% used medications increasing bleeding risk. In-hospital mortality was 18.7%, with no significant association for oral anticoagulants ( = 0.275) or NSAIDs ( = 0.324). Sepsis, heart failure, chronic renal failure, and malignancy were strongly linked to mortality in univariate analysis; multivariate analysis confirmed sepsis and malignancy as independent predictors, with a trend for heart failure. AIMS65 ≥ 2 (sensitivity 90.1%, AUC = 0.920) and Rockall ≥ 6 (sensitivity 91.7%, AUC = 0.822) were both effective in predicting mortality, with risk rising cumulatively with higher scores ( < 0.001). : In-hospital mortality after upper GI bleeding is high in elderly patients with multiple comorbidities, mainly from sepsis, malignancy, and heart failure. AIMS65 and Rockall scores effectively predict mortality and may support earlier intervention. The small, high-risk cohort limits generalizability, underscoring the need for multicenter validation.
本研究旨在确定合并症老年患者上消化道(GI)出血后的院内死亡率。此外,该研究试图确定使用AIMS65和Rockall评分预测高危患者的有效临界值,并评估口服抗凝剂和非甾体抗炎药(NSAID)的使用对死亡率的影响。
对2023年1月至2024年6月期间因上消化道出血入院的64例60岁及以上且至少患有一种合并症的患者进行了一项回顾性队列研究。为每位患者计算AIMS65和Rockall评分。使用包括ROC分析和Kaplan-Meier生存曲线在内的统计方法分析了这些评分、药物使用与死亡率之间的关系。
平均年龄为77.6岁,所有患者至少患有一种慢性病;57.8%的患者使用增加出血风险的药物。院内死亡率为18.7%,口服抗凝剂(P = 0.275)或非甾体抗炎药(P = 0.324)与死亡率无显著关联。在单因素分析中,脓毒症、心力衰竭、慢性肾衰竭和恶性肿瘤与死亡率密切相关;多因素分析证实脓毒症和恶性肿瘤是独立的预测因素,心力衰竭有相关趋势。AIMS65≥2(敏感性90.1%,AUC = 0.920)和Rockall≥6(敏感性91.7%,AUC = 0.822)均能有效预测死亡率,且随着评分升高风险累积增加(P < 0.001)。
合并多种合并症的老年患者上消化道出血后的院内死亡率很高,主要源于脓毒症、恶性肿瘤和心力衰竭。AIMS65和Rockall评分能有效预测死亡率,并可能支持早期干预。该小型高危队列限制了研究结果的普遍性,凸显了多中心验证的必要性。